Subscribe to Newsletter

Content by Stephanie Vine:

Business & Regulation Profession

Leadership: Keeping the Focus on Innovation

| Stephanie Vine | 4 min read

Life sciences is one of the most innovative industries in the world. What are the leadership skills required?

Business & Regulation Standards & Regulation

Why Are Some Medicines Linked to Suicide?

| Stephanie Vine | 3 min read

The EMA is reviewing whether certain Novo Nordisk drugs are linked to suicidal thoughts

Discovery & Development Drug Discovery

The PEPITEM Pathway – and the Path to New Obesity Treatments

| Stephanie Vine | 6 min read

The world needs new medicines to treat obesity-related conditions. Here’s what researchers at the UK’s University of Birmingham are doing about it.

Discovery & Development Advanced Medicine

Video Interview: Phil Vanek on the Importance of Regulatory Harmonization

| Stephanie Vine

We interviewed Gamma Biosciences’s CTO Phil Vanek to learn more about the current state of the Cell and Gene Industry

Manufacture Facilities

Pfizer to Rebuild Plant Damaged by Tornado

| Stephanie Vine | 3 min read

Both the FDA and Pfizer have released statements in the aftermath of the North Carolina tornado.

Discovery & Development Advanced Medicine

Video: Angela Osborne Discusses the Latest Cell and Gene Industry Trends

| Stephanie Vine

Check out our latest video interview with Angela Osborne who discusses the latest cell and gene industry trends.

Business & Regulation Digital Technologies

The ADHD Video Game – for Adults

| Stephanie Vine | 2 min read

Akili Interactive releases a new version of its ADHD treatment game for adults.

Business & Regulation Business Practice

Enter the Humira Biosimilars

| Stephanie Vine | 2 min read

Humira biosimilars finally launch on the US market

Business & Regulation Business Practice

Drug Pricing Lawsuits Ramp Up

| Stephanie Vine | 5 min read

More pharma stakeholders are launching lawsuits over the US government’s Inflation Reduction Act.

Discovery & Development Drug Discovery

Enhancing CRISPR-Cas9

| Stephanie Vine | 3 min read

Is safeguard sgRNA the key to reducing the off-target effects of gene editing, while increasing its potential applications?

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register